Literature DB >> 30466027

Agreement between digital breast tomosynthesis and pathologic tumour size for staging breast cancer, and comparison with standard mammography.

M Luke Marinovich1, Daniela Bernardi2, Petra Macaskill3, Anna Ventriglia2, Vincenzo Sabatino2, Nehmat Houssami3.   

Abstract

PURPOSE: Tomosynthesis is proposed to improve breast cancer assessment and staging. We compared tomosynthesis and mammography in estimating the size of newly-diagnosed breast cancers.
METHODS: All pathologically-confirmed cancers detected in the STORM-2 trial (90 cancers, 85 women) were retrospectively measured on tomosynthesis by two independent readers. One reader also measured cancers on mammography. Relative mean differences (MDs) and 95% limits of agreement (LOA) with pathology were estimated for tomosynthesis and mammography within a single reader (Analysis 1) and between two readers (Analysis 2).
RESULTS: Where cancers were detected and hence measured by both tests, tomosynthesis overestimated pathologic size relative to mammography (Analysis 1: MD 5% versus 1%, Analysis 2: 7% versus 3%; P = 0.10 both analyses). There was similar, large measurement variability for both tests (LOA range: -60% to +166%). Overestimation by tomosynthesis was attributable to the subgroup with dense breasts (MDs = 12-13% versus 4% for mammography). There was low average bias for both tests in the low-density subgroup (MDs = 0-4%). LOA were larger in dense breasts for both tomosynthesis and mammography (P ≤ 0.02 all comparisons). Cancers detected only by tomosynthesis were more frequently in dense breasts (60-68%): for those tumours size was estimated with increased measurement variability (LOA ranging from -75% to +293%).
CONCLUSIONS: On average, tomosynthesis overestimates pathologic tumour size in women with dense breasts; that difference is more likely to impact management in women with larger tumours. The main advantage of tomosynthesis appears to be detecting mammographically-occult cancers; however tomosynthesis less accurately measured those cancers in dense breasts (large measurement variability).
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Accuracy; Breast cancer; Mammography; Staging; Tomosynthesis; Tumour size

Mesh:

Year:  2018        PMID: 30466027     DOI: 10.1016/j.breast.2018.11.001

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  7 in total

Review 1.  Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review.

Authors:  Stephanie Kavan; Torben A Kruse; Marianne Vogsen; Malene G Hildebrandt; Mads Thomassen
Journal:  Cancer Metastasis Rev       Date:  2022-03-14       Impact factor: 9.237

Review 2.  Current and Developing Liquid Biopsy Techniques for Breast Cancer.

Authors:  Hsing-Ju Wu; Pei-Yi Chu
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

Review 3.  Circulating tumor cells in the early detection of human cancers.

Authors:  Zixin Feng; Junyu Wu; Yuanjun Lu; Yau-Tuen Chan; Cheng Zhang; Di Wang; Dan Luo; Yuan Huang; Yibin Feng; Ning Wang
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

4.  Digital breast tomosynthesis: sensitivity for cancer in younger symptomatic women.

Authors:  Patsy Whelehan; Kulsam Ali; Sarah Vinnicombe; Graham Ball; Julie Cox; Paul Farry; Maggie Jenkin; Keith Lowry; Stuart A McIntosh; Rachel Nutt; Rachel Oeppen; Michael Reilly; Michaela Stahnke; Jim Steel; Yee Ting Sim; Violet Warwick; Louise Wilkinson; Dimitrios Zafeiris; Andrew J Evans
Journal:  Br J Radiol       Date:  2021-01-07       Impact factor: 3.039

Review 5.  Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies.

Authors:  Marta Tellez-Gabriel; Erik Knutsen; Maria Perander
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

6.  METTL3 Accelerates Breast Cancer Progression via Regulating EZH2 m6A Modification.

Authors:  Shaojun Hu; Yang Song; Yu Zhou; Yu Jiao; Guopeng Li
Journal:  J Healthc Eng       Date:  2022-03-29       Impact factor: 2.682

7.  Synthesis, radiolabelling, and biological assessment of folic acid-conjugated G-3 99mTc-dendrimer as the breast cancer molecular imaging agent.

Authors:  Saedeh Zamani; Mehdi Shafeie-Ardestani; Ahmad Bitarafan-Rajabi; Ali Khalaj; Omid Sabzevari
Journal:  IET Nanobiotechnol       Date:  2020-09       Impact factor: 1.847

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.